We report the therapeutic results of 20 cases of encephaloceles in our study at the paediatric surgery department in Bangui.

Pattern Beauty is prioritizing brand awareness after six years of “tremendous growth,” co-chief executive officer Christiane Pendarvis said, while targeting longer-term global expansion following its ...

Subcutaneous administration of the anti-PD-1 monoclonal antibody toripalimab achieves similar drug exposure as the intravenous formulation in advanced non-squamous non-small cell lung cancer (NSCLC), ...

Growing up, Ivan’s daughter, Angelica Gayler, 23, was no stranger to her dad’s physical Parkinson’s symptoms. But it wasn’t until she stepped in as his caregiver at age 18 that she realized the full ...

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for autologous stem cell transplant. The U.S. Food and Drug Administration ...

Everyday it feels like yet another product launches, and to be quite honest, a lot of them miss the mark. A solid roll out and marketing campaign is one thing, but whether or not a product is actually ...

A Prescription Drug User Fee Act target date of May 24, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License ...

Milwaukee's Woodland Pattern cultural center is moving from Riverwest to a larger building in Bay View. The new location is four times larger and was more affordable than renovating its current home.

The full results of a phase 3 clinical trial showed that patients with moderate-to-severe active systemic lupus erythematosus (SLE) who received standard treatment achieved greater reductions in ...

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.